Literature DB >> 11728972

Mechanisms activated by kidney disease and the loss of muscle mass.

W E Mitch1, S R Price.   

Abstract

The daily turnover of cellular proteins is large, with amounts equivalent to the protein contained in 1.0 to 1.5 kg of muscle. Consequently, even a small, persistent increase in the rate of protein degradation or decrease in protein synthesis will result in substantial loss of muscle mass. Activation of protein degradation in the ubiquitin-proteasome system is the mechanism contributing to loss of muscle mass in kidney disease. Because other catabolic conditions also stimulate this system to cause loss of muscle mass, the identification of activating signals is of interest. A complication of kidney disease, metabolic acidosis, activates this system in muscle by a process that requires glucocorticoids. The influence of inflammatory cytokines on this system in muscle is more complicated, as evidence indicates that cytokines suppress the system, but glucocorticoids block the effect of cytokines to slow protein breakdown in the system. New information identifying mechanisms that activate protein breakdown and the rebuilding of muscle fibers would lead to therapies that successfully prevent the loss of muscle mass in kidney disease and other catabolic illnesses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728972     DOI: 10.1053/ajkd.2001.29249

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

1.  Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease.

Authors:  Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; Stacey E Jolly; Edgard Wehbe; Rupesh Raina; James F Simon; Titte R Srinivas; Anil Jain; Martin J Schreiber; Joseph V Nally
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

2.  The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

Authors:  James T Dalton; Kester G Barnette; Casey E Bohl; Michael L Hancock; Domingo Rodriguez; Shontelle T Dodson; Ronald A Morton; Mitchell S Steiner
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-08-02       Impact factor: 12.910

3.  Association between inflammatory-related disease burden and frailty: results from the Women's Health and Aging Studies (WHAS) I and II.

Authors:  Sandy S Chang; Carlos O Weiss; Qian-Li Xue; Linda P Fried
Journal:  Arch Gerontol Geriatr       Date:  2011-07-16       Impact factor: 3.250

4.  Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy: The BIOCRT study.

Authors:  Neal A Chatterjee; Jagmeet P Singh; Jackie Szymonifka; Roderick C Deaño; Wai-Ee Thai; Bryan Wai; James K Min; James L Januzzi; Quynh A Truong
Journal:  Int J Cardiol       Date:  2015-12-11       Impact factor: 4.164

Review 5.  Muscle atrophy in chronic kidney disease results from abnormalities in insulin signaling.

Authors:  S Russ Price; Jennifer L Gooch; Sue K Donaldson; Tiffany K Roberts-Wilson
Journal:  J Ren Nutr       Date:  2010-09       Impact factor: 3.655

Review 6.  Brain-derived neurotrophic factor (BDNF): a multifaceted marker in chronic kidney disease.

Authors:  Baris Afsar; Rengin Elsurer Afsar
Journal:  Clin Exp Nephrol       Date:  2022-08-28       Impact factor: 2.617

7.  Reduced albumin levels and utilization of arteriovenous access in pediatric patients with systemic lupus erythematosus (SLE).

Authors:  Sangeeta D Sule; Jeffrey J Fadrowski; Barbara A Fivush; Gregory Gorman; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2007-09-28       Impact factor: 3.714

Review 8.  Muscle wasting in hemodialysis patients: new therapeutic strategies for resolving an old problem.

Authors:  Chun-Ting Chen; Shih-Hua Lin; Jin-Shuen Chen; Yu-Juei Hsu
Journal:  ScientificWorldJournal       Date:  2013-12-05

9.  Chapter 3: Management of progression and complications of CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01

10.  Chapter 5: Referral to specialists and models of care.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.